Litigation Details for Onyx Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
✉ Email this page to a colleague
Onyx Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
Docket | ⤷ Sign Up | Date Filed | 2017-04-20 |
Court | District Court, D. Delaware | Date Terminated | 2018-02-14 |
Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
Jury Demand | None | Referred To | |
Patents | 7,232,818; 7,417,042; 7,491,704; 7,737,112; 8,129,346; 8,207,125; 8,207,126; 8,207,127; 8,207,297 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Onyx Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.
Biologic Drugs cited in Onyx Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.
Details for Onyx Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2018-02-12 | 16 | Product”) before the expiration of U.S. Patent Nos. 7,417,042; 7,232,818; 7,491,704; 7,737,112; 8,129,346;…and 8,207,297 (“the Patents-in-Suit”) on the basis that certain claims of the Patents-in-Suit are invalid…dismiss its claims alleging infringement of the Patents-in-Suit by Teva’s ANDA Product or ANDA No. 210170… 14 February 2018 1:17-cv-00449 830 Patent None District Court, D. Delaware | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |